Drug intelligence / Profile preview

INO-3605

Development stage: Unknown
Lead developer: Inovio Pharmaceuticals
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

INO-3605 is a DNA vaccine developed by Inovio Pharmaceuticals. It is comprised of plasmids encoding influenza hemagglutinin proteins, specifically H1 and H5. The vaccine is designed to be administered intradermally, followed by in vivo electroporation using the CELLECTRA®-3P device, to enhance the delivery of the plasmids into cells and stimulate an immune response. It is currently being evaluated in clinical trials for its safety, tolerability, and immunogenicity as a potential vaccine against influenza.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on INO-3605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INO-3605.

Explore the full profile